Clinical Trial Update: Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC) [Phase 2]

View source ↗

Summary

The Phase 2 study of visilizumab for intravenous steroid-refractory ulcerative colitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Abbott | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED